ABM 1381
Alternative Names: ABM-1381Latest Information Update: 30 Sep 2020
At a glance
- Originator ABM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 30 Sep 2020 ABM 1381 is available for licensing as of 30 Sep 2020. http://www.abmtx.com/
- 30 Sep 2020 ABM Therapeutics plans preclinical development in Cancer (Metastatic disease) (ABM Therapeutics pipeline, September 2020)